QUOTE AND NEWS
SeekingAlpha  Dec 3  Comment 
newratings.com  Apr 28  Comment 
WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc (BMRN) said Monday the European Commission has granted marketing authorization for Vimizim, the first specific treatment approved in the European Union for Mucopolysaccharidosis type IVA (MPS IVA;...
DailyFinance  Jan 7  Comment 
CES (Booth #9839) —DTS, Inc. (Nasdaq:DTSI), a leader in high-definition audio solutions and audio enhancement technologies, announced today that it has teamed up with Internet Video Archive (IVA), the world’s...
Benzinga  Nov 19  Comment 
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) voted in favor of approval of Vimizim for the treatment of Morquio A...
Benzinga  Nov 19  Comment 
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that NASDAQ has halted trading of the company's stock. The U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) is meeting today to...
Cloud Computing  Jun 4  Comment 
CodeBaby, a leading intelligent virtual assistant (IVA) technology provider for the benefits health insurance and provider industries, today announced that it has contracted with CareFirst BlueCross BlueShield (CareFirst), the largest health...
Globe Newswire  Mar 8  Comment 
Largest Phase 3 ERT Study to Date in a Lysosomal Storage Disease Results Expected in the Fourth Quarter of 2012 NOVATO, Calif., March 8, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that enrollment is complete
StreetInsider.com  Nov 29  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/BioMarin+%28BMRN%29+Initiates+GALNS+Phase+2+in+Patients+%3C+5-Years-Old+w+MPS+IVA/6981975.html for the full story.





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki